Click here to view the printer friendly version of this press release
Manhattan Scientifics Inc. is pleased to announce that its affiliate company, Imagion Biosystems Limited (“Imagion”), formerly known as Senior Scientific, LLC, filed a prospectus with the Australian Securities and Investment Commission and applied to the Australian Securities Exchange for an Initial Public Offering ("IPO") to raise up to A$12 million at A$0.20 per share.
Senior Scientific was acquired in June 2011 by Manhattan Scientifics. In November 2016, Senior Scientific merged with Imagion Biosystems, Inc., a Nevada corporation (“Imagion Nevada”). In December 2016, Imagion then acquired all of the outstanding shares of Imagion Nevada. As a result of this restructuring, Manhattan Scientifics received over 62.4 million shares in Imagion, presently equal to 50.1% ownership of Imagion.
Funds raised in the IPO are expected to be used in Imagion’s efforts to move to clinical product development followed by human clinical testing. Assuming the closing of the IPO and the issuance of additional shares to Manhattan Scientifics from the conversion of a note, Manhattan Scientifics is projected to own approximately 64.1 million shares equal to approximately 29.2% of Imagion.
Manny Tsoupanarias, Chief Executive Officer of Manhattan Scientifics commented: “MHTX shareholders today continue to own what they always owned in the past, a substantial interest in our cancer diagnostic technology. They own a portion of Imagion (Senior Scientific) today by virtue of their ownership of MHTX shares. While Australian securities laws dictate that non-Australian citizens may not participate in the Imagion IPO, non-Australian investors may be able to purchase Imagion shares in the market once the IPO is completed.”
This is not an offer to sell or a solicitation of any offer to buy any securities. Offers are made only by prospectus or other offering materials. The IPO is not being offered to investors outside of Australia. Australian investors can review the prospectus at https://imagionbiosystems.com/investor-relations/.
Manhattan Scientifics Inc. (www.mhtx.com) is focused on commercialization of disruptive technologies in the nano medicine space.
This press release contains forward-looking statements, which are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. Management at Manhattan Scientifics believes that purchase of its shares should be considered to be at the high end of the risk spectrum. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.